• Home
• Archive
• Rules for Authors
• Policies on Conflict of Interest, Human and animal rights, and Informed Consent
• Peer reviewering policy
• Editorial Board
• Certificate
• Editorial Ethics
• Contacts

Issue 4

Journal for Veterinary Medicine, Biotechnology and Biosafety

Volume 1, Issue 4, December 2015, Pages 9–15

ISSN 2411-3174 (print version) ISSN 2411-0388 (online version)

Biotechnological aspects of Amixin^® application as an antiviral drug for treatment of pigs and chicken

Buzun A. I., Kolchyk O. V., Stegniy M. Yu, Bobrovitska I. A., Stegniy A. B.

National Scientific Center ‘Institute of Experimental and Clinical Veterinary Medicine’, Kharkiv, Ukraine, e-mail: epibuz@ukr.net

Download PDF (print version)

Citation for print version: Buzun, A. I., Kolchyk, O. V., Stegniy, M. Yu, Bobrovitska, I. A. and Stegniy, A. B. (2015) ‘Biotechnological aspects of Amixin^® application as an antiviral drug for treatment of pigs and chicken’, Journal for Veterinary Medicine, Biotechnology and Biosafety, 1(4), pp. 9–15.

Download PDF (online version)

Citation for online version: Buzun, A. I., Kolchyk, O. V., Stegniy, M. Yu, Bobrovitska, I. A. and Stegniy, A. B. (2015) ‘Biotechnological aspects of Amixin^® application as an antiviral drug for treatment of pigs and chicken’, Journal for Veterinary Medicine, Biotechnology and Biosafety. [Online] 1(4), pp. 9–15. Available at: http://jvmbbs.kharkov.ua/archive/2015/volume1/issue4/oJVMBBS_2015014_009-015.pdf

Summary. Veterinary drug AmixinR, active substance dihydrochloride 2,7-bis[2-(diethylamine)ethoxy]fluorene-9-one (AMX), was tested for its antiviral activity with using of the epizootic relevance for Ukraine the infectious agents of Pseudorabies (PR), Teschovirus encephalomyelitis (TEM), classical swine fever (CSF), porcine reproductive and respiratory syndrome pigs (PRRS), 2nd type of porcine circovirus (PCV-2) and parvovirus infections (PPVI), swine (SIV) and avian influenza viruses (AIV). The influence of this drug on agents of the avian mycoplasmosis (Myc) and pasteurellosis (Past) was also learned. AMX action was tested in the concentrations of 0.5–15 mg/ml, expositions for 0.25–12 hours and at the room temperature. Under these conditions, the inactivation of 20–60% (the highest concentrations more likely) the 1000 infectious units (TCID, ELD or PFU_50/ml, respectively) of all viruses was resulted. The 5000 ELD_50/ml of the SIV and AIV viruses were inactivated for 5 hours almost totally. Moderate toxicity of AMX was registered in it doses ≥1 mg/ml (P≤0.01) for tube cultures of PK-15 cell line and Marc-145. At the same time AMX doses ≥0.125 mg/ml inhibited by 20–75% of infective activities of agents of the PR, PRRS, PCV-2, PPVI (n=42, P≤0.01) in cell cultures Marc-145 and PK-15, respectively. The toxicity of the drug for 7–9-days-old embryos chickens began to emerge with a concentration of 1.5 mg/ml (n=18, P≤0.01). Its virostatic effect on SIV, AIV and PR agents was manifested in doses ≥0.25 mg/ml (n=24, P≤0.01). AMX was administrated in a single dose of 540 mg ana partes with sunflower oil and showed no toxicity for suckling piglets (n=4, P≤0.01) and 10-days-old chickens (n=10, P≤0.005). At the same time the antibiotic resistant Myc and Past from the blood of chicken infected by natural mixes of these agents, acquire the sensitivity to commercial food antibiotic after 5-days course of treatment by AMX. These data is interpreted the mechanism of therapeutic and preventive action of AMX through direct antivirus activity. The hypothesis of acquires the antibiotic sensitivity by pathogenic bacteria throughout its bacteriophages inhibition is proposed.

Keywords: Amixin, toxicity, antiviral activity, porcine viruses, avian agents, bacteriophages

References:

Andronati, S. A., Litvinova, L. A. and Golovenko, N. Y. (1999) ‘The oral inducer of endogenous interferon “Amiksin” and its analogs (review of the literature and our own research)’ [Peroral’nyy induktor endogennogo interferona “Amiksin” i ego analogi (obzor literatury i sobstvennykh issledovaniy)], Journal of Academy of Medical Sciences of Ukraine [Zhurnal Akademii meditsinskikh nauk Ukrainy], 1, pp. 53–66. [in Russian]

Buzun, A. I., Prokhoryatova, O. V. and Kolchyk, O. V. (2001) Guidelines for control of stable form of RNPI [Metodychni rekomendatsii shchodo kontroliuvannia stiikykh form RNIS]. Kharkiv: National Scientific Center ‘Institute of Experimental and Clinical Veterinary Medicine’. [in Ukrainian]

Demchenko, E. V., Ivanchenko, G. F., Prozorovskaya, K. N., Bocharov, A. F. and Boykova, N. E. (2000) ‘Chlamydial laryngitis: clinical picture and amixine treatment’ [Klinika i lechenie khlamidioznogo laringita s primeneniem amiksina], Vestnik otorinolaringologii, 5, pp. 58–60. PMID: 11051861. [in Russian]

Drew, T. (2011) ‘The emergence and evolution of swine viral diseases: To what extent have husbandry systems and global trade contributed to their distribution and diversity?’, Revue scientifique et technique (International Office of Epizootics), 30(1), pp. 95–106. Available at: http://www.researchgate.net/publication/51540841

Erice, A., Balfour, H. H., Myers, D. E., Leske, V. L., Sannerud, K. J., Kuebelbeck, V., Irvin, J. D. and Uckun, F. M. (1993) ‘Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein’, Antimicrobial Agents and Chemotherapy, 37(4), pp. 835–838. doi: http://dx.doi.org/10.1128/AAC.37.4.835

Ershov, F. I., Batkaev, E. A., Golovkin, V. I., Kisilev, O. I. and Tur’yanov, M. K. (1998) Amixin. Application in therapy of acute and chronic viral diseases [Amiksin. Primenenie v terapii pri ostrykh i khronicheskikh virusnykh zabolevaniyakh]. Moscow. [in Russian]

Lyakhov, S. A. and Litvinova, L. A. (2008) ‘Mechanisms of the antiviral activity of amixin (review of literature). 2. Antiviral activity and influence on some biochemical processes’ [Mekhanizmy protivovirusnoy aktivnosti amiksina (obzor literatury). 2. Protivovirusnaya aktivnost’ i vliyanie na nekotorye biokhimicheskie protsessy], Modern Infection [Suchasni infektsii], 2, pp. 112–116. [in Russian]

Mashkovskyi, M. D. (1997) Therapeutic preparations [Likarski preparaty]. 13^th ed. Kharkiv: Torsinh. [in Ukrainian]

Reed, L. J. and Muench, H. (1938) ‘A simple method of estimating fifty per cent endpoints’, American Journal of Hygiene, 27(3), pp. 493–497. Available at: http://aje.oxfordjournals.org/content/27/3/493.full.pdf

Stefanov, A. V. (ed.) (2002) Preclinical studies of medicinal products: Guidelines [Doklinicheskie issledovaniya lekarstvennykh sredstv: metodicheskie rekomendatsii]. Kiev: Avitsenna. [in Russian]

Zhu, L., Zhou, Y. and Tong, G. (2012) ‘Mechanisms of suppression of interferon production by porcine reproductive and respiratory syndrome virus’, Acta virologica, 56(1), pp. 3–9. doi: http://dx.doi.org/10.4149/av_2012_01_3

Zholobak, N. M., Kavok, N. S., Bogorad-Kobelska, O. S., Borovoy, I. A., Malyukina, M. Y. and Spivak, M. Y. (2012) ‘Effect of tilorone and its analogues on the change in rat hepatocyte mitochondrial potential’, Fiziolohichnyi zhurnal, 58(2), pp. 39–43. Available at: http://biph.kiev.ua/fiziol/2012_V.58/Fiziologichnyi Zhurnal 58(2)_2012/Fiziologichnyi Zhurnal 58(2)__2012_39-43.pdf